IN2012DN02423A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02423A
IN2012DN02423A IN2423DEN2012A IN2012DN02423A IN 2012DN02423 A IN2012DN02423 A IN 2012DN02423A IN 2423DEN2012 A IN2423DEN2012 A IN 2423DEN2012A IN 2012DN02423 A IN2012DN02423 A IN 2012DN02423A
Authority
IN
India
Prior art keywords
mif
cxcr2
cxcr4
homomultimer
inhibits
Prior art date
Application number
Other languages
English (en)
Inventor
Jurgen Bernhagen
Christian Weber
Benedikt Vollrath
Court Turner
Joshua Robert Schultz
Alma Zernecke
Sergio Duron
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of IN2012DN02423A publication Critical patent/IN2012DN02423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN2423DEN2012 2009-09-23 2010-09-23 IN2012DN02423A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (fr) 2009-09-23 2010-09-23 Méthodes de traitement d'une inflammation

Publications (1)

Publication Number Publication Date
IN2012DN02423A true IN2012DN02423A (fr) 2015-08-21

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2423DEN2012 IN2012DN02423A (fr) 2009-09-23 2010-09-23

Country Status (9)

Country Link
EP (1) EP2480579A4 (fr)
KR (1) KR20120105429A (fr)
CN (1) CN102725311A (fr)
AU (1) AU2010298249A1 (fr)
BR (1) BR112012006468A2 (fr)
CA (1) CA2773978A1 (fr)
IN (1) IN2012DN02423A (fr)
MX (1) MX2012003514A (fr)
WO (1) WO2011038149A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010955A1 (fr) 2011-07-15 2013-01-24 Morphosys Ag Anticorps à réactions croisées anti-facteur inhibiteur de la migration des macrophages (mif) et anti-d-dopachrome tautomérase (d-dt)
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20150140005A1 (en) * 2012-05-17 2015-05-21 Cyon Therapeutics Inc. Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
WO2015071416A2 (fr) * 2013-11-14 2015-05-21 Baxter Healthcare Sa Facteur d'inhibition de la migration des macrophages en tant que cible therapeutique
CN113893252A (zh) 2016-03-11 2022-01-07 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
WO2020139620A1 (fr) * 2018-12-26 2020-07-02 Colgate-Palmolive Company Biomarqueurs de dérégulation des neutrophiles en tant que diagnostic de gingivite
JP2023517616A (ja) * 2020-03-11 2023-04-26 バイオラインアールエックス・リミテッド 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
WO2021219495A1 (fr) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Méthodes de traitement ou de prévention d'une infection virale ou d'inhibition de la réplication virale
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用
US12558549B2 (en) 2022-10-28 2026-02-24 Medtronic, Inc. Lead based measurements for tongue movement determination
EP4378319A1 (fr) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprenant des peptides bioactifs
CN119318647A (zh) * 2024-08-14 2025-01-17 南方医科大学 Sb225002在制备治疗心肌梗死的药物中的应用、治疗心肌梗死的组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312318B2 (en) * 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2003072753A2 (fr) * 2002-02-27 2003-09-04 Emory University Complexes de liaison multimeres
US7897349B2 (en) * 2003-12-30 2011-03-01 The United States Of America As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ588033A (en) * 2008-03-20 2012-11-30 Carolus Therapeutics Inc Methods of treating a mif-mediated disorder
WO2010056910A2 (fr) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Procedes de traitement de troubles cardio-vasculaires

Also Published As

Publication number Publication date
EP2480579A2 (fr) 2012-08-01
CN102725311A (zh) 2012-10-10
AU2010298249A1 (en) 2012-04-19
BR112012006468A2 (pt) 2016-08-09
KR20120105429A (ko) 2012-09-25
CA2773978A1 (fr) 2011-03-31
WO2011038149A2 (fr) 2011-03-31
WO2011038149A3 (fr) 2011-10-27
MX2012003514A (es) 2012-04-19
EP2480579A4 (fr) 2013-07-31

Similar Documents

Publication Publication Date Title
IN2012DN02423A (fr)
WO2009117710A3 (fr) Procédés de traitement d'inflammations
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
WO2008122049A3 (fr) Procédés et compositions pour la réduction des effets secondaires des traitements thérapeutiques
MY191313A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
EP3489360A3 (fr) Modulation de l'arn retenu nucléaire
MX2011007930A (es) Conjugados de insulina cristalina.
WO2010005524A3 (fr) Systèmes et procédés d’utilisation afférents dans le traitement des anévrismes aortiques abdominaux
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2009080800A3 (fr) Méthode pour réduire le tour de taille par l'administration de bactéries du genre bifidobacterium
IN2014DN08385A (fr)
WO2009016488A3 (fr) Compositions comprenant des antidépresseurs tétracycliques pour le traitement d'un cancer et procédés apparentés
WO2011044523A3 (fr) Compositions et procédés destinés à traiter l'obésité
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
EP2566502A4 (fr) Méthodes de traitement ou de prévention de troubles cardiovasculaires, et de fourniture d'une protection cardiovasculaire
WO2011041325A3 (fr) Procédés et compositions pour traitement de troubles viraux
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
AU2010298020A8 (en) Combination
WO2008073317A3 (fr) Cytarabine pour le traitement du gliome
TN2011000206A1 (en) Compositions and methods of use soluble thrombomodulin variants
PH12012500873A1 (en) Multilayer pharmaceutical composition that can be dispersed in water and which contains a combination of antimalarial agents
UA41936U (ru) Способ лечения крауроза вульвы в детском возрасте
UA83743C2 (ru) Способ профилактики и коррекции сниженных функциональных возможностей центральной нервной системы